<DOC>
	<DOC>NCT02106858</DOC>
	<brief_summary>To investigate and collect post-marketing data on the safety of Stivarga in real world practice in its registered indication(s) as required by Health Authority.</brief_summary>
	<brief_title>Stivarga Regulatory Post-Marketing Surveillance Study in Korea</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<criteria>Patients diagnosed with metastatic colorectal cancer or metastatic or unresectable locally advanced GIST(gastrointestinal stromal tumors) by physician. Patients who are prescribed with Stivarga for the first time. All contraindications according to the local marketing authorization have to be considered.</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Stivarga / Regorafenib / Metastatic Colorectal Cancer / Metastatic or unresectable locally advanced GIST (Gastrointestinal stromal tumors)</keyword>
</DOC>